Facility Expansion - Launching in Q3 2025, now open for projects!
Front facing image of blue building with the eirgen pharma logo at the top of the image
Eirgen Pharma’s new state-of-the-art facility expansion in Waterford significantly increases our capacity to support global partners. Designed for flexibility and scalability, it enables the manufacture of over 500 million oral solid dose units annually, including high-potency and non-potent products. This investment reflects our commitment to delivering science-led, high-quality pharmaceutical solutions — from clinical development to full commercial supply — all under one roof.
Eirgen Pharma’s expanded facility in Waterford boosts our capacity to over 500 million oral solid dose units annually. Purpose-built for flexibility and scalability, it supports high-potency and non-potent products from development through to commercial supply — reinforcing our commitment to quality, speed, and science-driven pharmaceutical solutions.
